Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells

Cell Death and Disease

Volumn 6, Issue 11, 2015, Pages

  Oliveira, L M A ^a,e   Falomir Lockhart, L J ^a,f   Botelho, M G ^a,g   Lin, K H ^a   Wales, P ^b   Koch, J C ^b   Gerhardt, E ^b   Taschenberger, H ^a,c   Outeiro, T F ^b,c   Lingor, P ^b,c   Schule B ^d   Arndt Jovin, D J ^a   Jovin, T M ^a  

^a MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c Deutsche Forschungsgemeinschaft   (Germany)

^d PARKINSON S INSTITUTE   (United States)

^e New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^f INSTITUTO DE INVESTIGACIONES BIOQUÍMICAS DE LA PLATA INIBIOLP   (Argentina)

^g FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 4 AMINOBUTYRIC ACID RECEPTOR; ALPHA SYNUCLEIN; DELTA LIKE HOMOLOG 1; G PROTEIN REGULATED INWARD RECTIFIER POTASSIUM CHANNEL 2; MESSENGER RNA; NUCLEAR RECEPTOR RELATED FACTOR 1; SHORT HAIRPIN RNA; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; SNCA PROTEIN, HUMAN;

ARTICLE; CELL MATURATION; DOPAMINERGIC NERVE CELL; GENE; GENE EXPRESSION PROFILING; GENE LOCUS; GENE NUMBER; GENE OVEREXPRESSION; GENE SILENCING; GENE TRIPLICATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INDUCED PLURIPOTENT STEM CELL; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; PARKINSON DISEASE; PRIORITY JOURNAL; SNCA GENE; CELL CULTURE; CELL DIFFERENTIATION; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY;

ALPHA-SYNUCLEIN; CELL DIFFERENTIATION; CELLS, CULTURED; GENE EXPRESSION PROFILING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; NEURONS; PARKINSON DISEASE;

EID: 84989857779     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.318     Document Type: Article

References (68)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-2066.
2. Reeve A, Simcox E, Turnbull D. Ageing and Parkinson's disease: Why is advancing age the biggest risk factor? Ageing Res Rev 2014; 14: 19-30.
3. Pan-Montojo F, Reichmann H. Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiology. Transl Neurodegener 2014; 3: 1-13.
4. Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol 2000; 247(Suppl 2): II3-10.
5. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840.
6. Bendor JT, Logan TP, Edwards RH. The function of alpha-synuclein. Neuron 2013; 79: 1044-1066.
7. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of alpha-synuclein: From structure and toxicity to therapeutic target. Nat Rev Neurosci 2013; 14: 38-48.
8. Silva BA, Breydo L, Uversky VN. Targeting the chameleon: A focused look at alpha-synuclein and its roles in neurodegeneration. Mol Neurobiol 2013; 47: 446-459.
9. Wales P, Pinho R, Lazaro DF, Outeiro TF. Limelight on alpha-synuclein: Pathological and mechanistic implications in neurodegeneration. J Parkinsons Dis 2013; 3: 415-459.
10. Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord 2013; 28: 811-813.
11. Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P et al. Alpha-synucleinopathy associated with G51D SNCA mutation: A link between Parkinson's disease and multiple system atrophy? Acta Neuropathol 2013; 125: 753-769.
12. Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J et al. Novel alphasynuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol Aging 2014; 35: 2180 e2181-2180 e2185.
13. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364: 1169-1171.
14. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
15. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009; 41: 1303-1307.
16. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41: 1308-1312.
17. Spencer CC, Plagnol V, Strange A, Gardner M, Paisan-Ruiz C, Band G et al. Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet 2011; 20: 345-353.
18. Chung CY, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR, Soldner F et al. Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. Science 2013; 342: 983-987.
19. Reinhardt P, Schmid B, Burbulla LF, Schondorf DC, Wagner L, Glatza M et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 2013; 12: 354-367.
20. Ryan SD, Dolatabadi N, Chan SF, Zhang X, Akhtar MW, Parker J et al. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1alpha transcription. Cell 2013; 155: 1351-1364.
21. Boulting G, Kiskinis E, Croft G, Amoroso M, Oakley D, Wainger B et al. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol 2011; 29: 279-286.
22. Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H et al. Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat Commun 2011; 2: 440.
23. Osafune K, Caron L, Borowiak M, Martinez R, Fitz-Gerald C, Sato Y et al. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol 2008; 26: 313-315.
24. Badger JL, Cordero-Llana O, Hartfield EM, Wade-Martins R. Parkinson's disease in a dish - using stem cells as a molecular tool. Neuropharmacology 2014; 76(Pt A): 88-96.
25. Mochizuki H, Choong CJ, Yasuda T. The promises of stem cells: Stem cell therapy for movement disorders. Parkinsonism Relat Disord 2014; 20(Suppl 1): S128-S131.
26. Byers B, Cord B, Nguyen HN, Schule B, Fenno L, Lee PC et al. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress. PLoS One 2011; 6: E26159.
27. Mak SK, Huang YA, Iranmanesh S, Vangipuram M, Sundararajan R, Nguyen L et al. Small molecules greatly improve conversion of human-induced pluripotent stem cells to the neuronal lineage. Stem Cells Int 2012; 2012: 140427.
28. Mak SK, Tewari D, Tetrud JW, Langston JW, Schule B. Mitochondrial dysfunction in skin fibroblasts from a Parkinson's disease patient with an alpha-synuclein triplication. J Parkinsons Dis 2011; 1: 175-183.
29. Flierl A, Oliveira LM, Falomir-Lockhart LJ, Mak SK, Hesley J, Soldner F et al. Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication. PLoS One 2014; 9: E112413.
30. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999; 122(Pt 8): 1437-1448.
31. Miller DW, Hague SM, Clarimon J, Baptista M, Gwinn-Hardy K, Cookson MR et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004; 62: 1835-1838.
32. Swistowski A, Peng J, Liu Q, Mali P, Rao MS, Cheng L et al. Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. Stem Cells 2010; 28: 1893-1904.
33. Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon H, Brundin P. Effect of mutant alphasynuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem 2002; 277: 38884-38894.
34. Lotharius J, Falsig J, van Beek J, Payne S, Dringen R, Brundin P et al. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopaminedependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci 2005; 25: 6329-6342.
35. Scholz D, Poltl D, Genewsky A, Weng M, Waldmann T, Schildknecht S et al. Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem 2011; 119: 957-971.
36. Schoenen J. The dendritic organization of the human spinal cord: The dorsal horn. Neuroscience 1982; 7: 2057-2087.
37. Ban BK, Jun MH, Ryu HH, Jang DJ, Ahmad ST, Lee JA. Autophagy negatively regulates early axon growth in cortical neurons. Mol Cell Biol 2013; 33: 3907-3919.
38. Chen JX, Sun YJ, Wang P, Long DX, Li W, Li L et al. Induction of autophagy by TOCP in differentiated human neuroblastoma cells lead to degradation of cytoskeletal components and inhibition of neurite outgrowth. Toxicology 2013; 310: 92-97.
39. Poole B, Ohkuma S. Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J Cell Biol 1981; 90: 665-669.
40. Schneider BL, Seehus CR, Capowski EE, Aebischer P, Zhang SC, Svendsen CN. Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation. Hum Mol Genet 2007; 16: 651-666.
41. Sanchez-Danes A, Richaud-Patin Y, Carballo-Carbajal I, Jimenez-Delgado S, Caig C, Mora S et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med 2012; 4: 380-395.
42. Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schule B et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007; 68: 916-922.
43. Luo Y. The function and mechanisms of Nurr1 action in midbrain dopaminergic neurons, from development and maintenance to survival. Int Rev Neurobiol 2012; 102: 1-22.
44. Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Bjorklund A. Alpha-synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med 2012; 4: 163ra156.
45. Bauer M, Szulc J, Meyer M, Jensen CH, Terki TA, Meixner A et al. Delta-like 1 participates in the specification of ventral midbrain progenitor derived dopaminergic neurons. J Neurochem 2008; 104: 1101-1115.
46. Jacobs FM, van der Linden AJ, Wang Y, von Oerthel L, Sul HS, Burbach JP et al. Identification of Dlk1, Ptpru and Klhl1 as novel Nurr1 target genes in meso-diencephalic dopamine neurons. Development 2009; 136: 2363-2373.
47. Liu G, Wang P, Li X, Li Y, Xu S, Ueda K et al. Alpha-synuclein promotes early neurite outgrowth in cultured primary neurons. J Neural Transm 2013; 120: 1331-1343.
48. Koch JC, Bitow F, Haack J, d'Hedouville Z, Zhang JN, Tonges L et al. Alpha-synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons. Cell Death Dis 2015; 6: E1811.
49. Neuner J, Ovsepian SV, Dorostkar M, Filser S, Gupta A, Michalakis S et al. Pathological alpha-synuclein impairs adult-born granule cell development and functional integration in the olfactory bulb. Nat Commun 2014; 5: 3915.
50. Winner B, Regensburger M, Schreglmann S, Boyer L, Prots I, Rockenstein E et al. Role of alpha-synuclein in adult neurogenesis and neuronal maturation in the dentate gyrus. J Neurosci 2012; 32: 16906-16916.
51. Lee HJ, Lee K, Im H. Alpha-synuclein modulates neurite outgrowth by interacting with SPTBN1. Biochem Biophys Res Commun 2012; 424: 497-502.
52. Lynch-Day MA, Mao K, Wang K, Zhao M, Klionsky DJ. The role of autophagy in Parkinson's disease. Cold Spring Harb Perspect Med 2012; 2: A009357.
53. Ebrahimi-Fakhari D, McLean PJ, Unni VK. Alpha-synuclein's degradation in vivo: Opening a new (cranial) window on the roles of degradation pathways in Parkinson disease. Autophagy 2012; 8: 281-283.
54. Xilouri M, Brekk OR, Stefanis L. Alpha-synuclein and protein degradation systems: A reciprocal relationship. Mol Neurobiol 2013; 47: 537-551.
55. Winslow AR, Chen CW, Corrochano S, Acevedo-Arozena A, Gordon DE, Peden AA et al. Alpha-synuclein impairs macroautophagy: Implications for Parkinson's disease. J Cell Biol 2010; 190: 1023-1037.
56. Le Grand JN, Gonzalez-Cano L, Pavlou MA, Schwamborn JC. Neural stem cells in Parkinson's disease: A role for neurogenesis defects in onset and progression. Cell Mol Life Sci 2015; 72: 773-797.
57. Wang S, Okun MS, Suslov O, Zheng T, McFarland NR, Vedam-Mai V et al. Neurogenic potential of progenitor cells isolated from postmortem human Parkinsonian brains. Brain Res 2012; 1464: 61-72.
58. Rodriguez-Leyva I, Calderon-Garciduenas AL, Jimenez-Capdeville ME, Renteria-Palomo AA, Hernandez-Rodriguez HG, Valdes-Rodriguez R et al. Alpha-synuclein inclusions in the skin of Parkinson's disease and parkinsonism. Ann Clin Transl Neurol 2014; 1: 471-478.
59. Rhinn H, Qiang L, Yamashita T, Rhee D, Zolin A, Vanti W et al. Alternative alpha-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology. Nat Commun 2012; 3: 1084.
60. Zharikov AD, Cannon JR, Tapias V, Bai Q, Horowitz MP, Shah V et al. shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson's disease model. J Clin Invest 2015; 125: 2721-2735.
61. Yasuda T, Nakata Y, Choong CJ, Mochizuki H. Neurodegenerative changes initiated by presynaptic dysfunction. Transl Neurodegener 2013; 2: 16.
62. Pacelli C, Giguere N, Bourque MJ, Levesque M, Slack RS, Trudeau LE. Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Curr Biol 2015; 27: 00884-00882.
63. Demetrius LA, Magistretti PJ, Pellerin L. Alzheimer's disease: The amyloid hypothesis and the Inverse Warburg effect. Front Physiol 2014; 5: 522.
64. Van Laar VS, Berman SB. The interplay of neuronal mitochondrial dynamics and bioenergetics: Implications for Parkinson's disease. Neurobiol Dis 2013; 51: 43-55.
65. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T et al. Fiji: An open-source platform for biological-image analysis. Nat Methods 2012; 9: 676-682.
66. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
67. Lizee G, Aerts JL, Gonzales MI, Chinnasamy N, Morgan RA, Topalian SL. Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression. Hum Gene Ther 2003; 14: 497-507.
68. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445-544.